Progression-free survival prediction in diffuse large B-cell lymphoma: where can we further improve?
INTRODUCTION Diffuse large B-cell lymphoma (DLBCL) is a biologically heterogeneous disease in which approximately one-third of patients experience primary refractoriness or relapse despite modern chemoimmunotherapy. Although clinical prognostic indices remain the cornerstone of risk stratification, they incompletely ca...